問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

許雅婷Hsu, Ya-Ting
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

121Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

許雅婷

List

167Cases

2022-06-01 - 2029-09-30

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-10-01 - 2030-12-31

Phase I

Active
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies

  • Condition/Disease

    Diffuse Large B-Cell Lymphoma、 Chronic Lymphocytic Leukemia 、B Cell Malignancies 、Non-Hodgkin's Lymphoma

  • Test Drug

    lozenges

Participate Sites
3Sites

Recruiting3Sites

2021-07-01 - 2029-05-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2024-02-01 - 2038-01-31

Phase III

Active
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

  • Condition/Disease

    Follicular Lymphoma (FL)

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2023-02-01 - 2030-01-31

Phase III

Active
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

  • Condition/Disease

    Diffuse Large B-Cell Lymphoma

  • Test Drug

    Epcoritamab

Participate Sites
4Sites

Recruiting4Sites

2022-10-01 - 2030-05-31

Phase III

Active
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

  • Condition/Disease

    Follicular Lymphoma (FL)

  • Test Drug

    Epcoritamab

Participate Sites
5Sites

Recruiting5Sites

2023-09-01 - 2023-12-31

Phase I/II

Completed
A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

  • Condition/Disease

    Leukemia, Myeloid, Acute

  • Test Drug

    Film coated Tablets

Participate Sites
3Sites

Terminated3Sites

2021-12-31 - 2025-10-01

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-12-01 - 2024-12-31

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2020-09-01 - 2025-05-14

Phase I

Completed
Phase Ib, Multi-center Study of Combining Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary Central Nervous System Lymphoma.

  • Condition/Disease

    Primary Central Nervous System Lymphoma (PCNSL)

  • Test Drug

    Acalabrutinib

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5 6 17
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB